Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Focken T, Liu S, Chahal N, Dauphinais M, Grimwood ME, Chowdhury S, Hemeon I, Bichler P, Bogucki D, Waldbrook M, Bankar G, Sojo LE, Young C, Lin S, Shuart N, Kwan R, Pang J, Chang JH, Safina BS, Sutherlin DP, Johnson JP Jr, Dehnhardt CM, Mansour TS, Oballa RM, Cohen CJ, Robinette CL.

ACS Med Chem Lett. 2016 Jan 19;7(3):277-82. doi: 10.1021/acsmedchemlett.5b00447. eCollection 2016 Mar 10.

2.

Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.

Kaila N, Follows B, Leung L, Thomason J, Huang A, Moretto A, Janz K, Lowe M, Mansour TS, Hubeau C, Page K, Morgan P, Fish S, Xu X, Williams C, Saiah E.

J Med Chem. 2014 Feb 27;57(4):1299-322. doi: 10.1021/jm401509e. Epub 2014 Feb 10.

PMID:
24512187
3.

Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.

Wan ZK, Chenail E, Li HQ, Ipek M, Xiang J, Suri V, Hahm S, Bard J, Svenson K, Xu X, Tian X, Wang M, Li X, Johnson CE, Qadri A, Panza D, Perreault M, Mansour TS, Tobin JF, Saiah E.

ACS Med Chem Lett. 2012 Nov 23;4(1):118-23. doi: 10.1021/ml300352x. eCollection 2013 Jan 10.

4.

Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.

Kaila N, Huang A, Moretto A, Follows B, Janz K, Lowe M, Thomason J, Mansour TS, Hubeau C, Page K, Morgan P, Fish S, Xu X, Williams C, Saiah E.

J Med Chem. 2012 Jun 14;55(11):5088-109. doi: 10.1021/jm300007n. Epub 2012 May 31.

PMID:
22651823
5.

Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).

Wu Y, Li J, Wu J, Morgan P, Xu X, Rancati F, Vallese S, Raveglia L, Hotchandani R, Fuller N, Bard J, Cunningham K, Fish S, Krykbaev R, Tam S, Goldman SJ, Williams C, Mansour TS, Saiah E, Sypek J, Li W.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):138-43. doi: 10.1016/j.bmcl.2011.11.046. Epub 2011 Nov 20.

PMID:
22153340
6.

Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016.

Wan ZK, Chenail E, Li HQ, Kendall C, Wang Y, Gingras S, Xiang J, Massefski WW, Mansour TS, Saiah E.

J Org Chem. 2011 Sep 2;76(17):7048-55. doi: 10.1021/jo200958a. Epub 2011 Aug 2.

PMID:
21736359
7.

PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.

Venkatesan AM, Chen Z, dos Santos O, Dehnhardt C, Santos ED, Ayral-Kaloustian S, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Chaudhary I, Mansour TS.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5869-73. doi: 10.1016/j.bmcl.2010.07.104. Epub 2010 Jul 30.

PMID:
20797855
8.

2-Aryl-4,5,6,7-tetrahydro-1,3-benzothiazol-7-ols as a class of antitumor agents selectively active in securin(-/-) cells.

Zhang N, Ayral-Kaloustian S, Niu C, Nguyen T, Upeslacis E, Mansour TS, Ragunathan S, Rosfjord E.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3903-5. doi: 10.1016/j.bmcl.2010.05.021. Epub 2010 May 12.

PMID:
20627558
9.

Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.

Chen Z, Venkatesan AM, Dehnhardt CM, Ayral-Kaloustian S, Brooijmans N, Mallon R, Feldberg L, Hollander I, Lucas J, Yu K, Kong F, Mansour TS.

J Med Chem. 2010 Apr 22;53(8):3169-82. doi: 10.1021/jm901783v.

PMID:
20334367
10.

Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

Tsou HR, MacEwan G, Birnberg G, Grosu G, Bursavich MG, Bard J, Brooijmans N, Toral-Barza L, Hollander I, Mansour TS, Ayral-Kaloustian S, Yu K.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2321-5. doi: 10.1016/j.bmcl.2010.01.135. Epub 2010 Feb 2.

PMID:
20188552
11.

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.

J Med Chem. 2010 Mar 25;53(6):2636-45. doi: 10.1021/jm901830p.

PMID:
20166697
12.

Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.

Perreault M, Will S, Panza D, Gareski T, Harding K, Kubasiak D, Jalenak M, Gartrell K, Wang S, Bollag G, Artis DR, Ibrahim PN, Womack P, Lin JJ, Saiah E, Mansour TS, Vlasuk GP, Erbe DV, Tobin JF.

Diabetes Obes Metab. 2010 Mar;12(3):234-45. doi: 10.1111/j.1463-1326.2009.01157.x.

PMID:
20152000
13.

Stereoselective synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179.

Chen Z, Venkatesan AM, Dos Santos O, Delos Santos E, Dehnhardt CM, Ayral-Kaloustian S, Ashcroft J, McDonald LA, Mansour TS.

J Org Chem. 2010 Mar 5;75(5):1643-51. doi: 10.1021/jo9026269.

PMID:
20112997
14.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ.

Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12.

15.

Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition.

Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.

J Med Chem. 2010 Jan 28;53(2):897-910. doi: 10.1021/jm901370m.

PMID:
20025292
16.

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

Dehnhardt CM, Venkatesan AM, Delos Santos E, Chen Z, Santos O, Ayral-Kaloustian S, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Chaudhary I, Yu K, Gibbons J, Abraham R, Mansour TS.

J Med Chem. 2010 Jan 28;53(2):798-810. doi: 10.1021/jm9014982.

PMID:
19968288
17.

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.

Venkatesan AM, Dehnhardt CM, Chen Z, Santos ED, Dos Santos O, Bursavich M, Gilbert AM, Ellingboe JW, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham R, Mansour TS.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):653-6. doi: 10.1016/j.bmcl.2009.11.057. Epub 2009 Dec 1.

PMID:
19954970
18.

Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.

Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K.

J Med Chem. 2010 Jan 14;53(1):452-9. doi: 10.1021/jm901427g.

PMID:
19928864
19.

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

Verheijen JC, Richard DJ, Curran K, Kaplan J, Lefever M, Nowak P, Malwitz DJ, Brooijmans N, Toral-Barza L, Zhang WG, Lucas J, Hollander I, Ayral-Kaloustian S, Mansour TS, Yu K, Zask A.

J Med Chem. 2009 Dec 24;52(24):8010-24. doi: 10.1021/jm9013828.

PMID:
19894727
20.

Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia.

Liang S, Pong K, Gonzales C, Chen Y, Ling HP, Mark RJ, Boschelli F, Boschelli DH, Ye F, Barrios Sosa AC, Mansour TS, Frost P, Wood A, Pangalos MN, Zaleska MM.

J Pharmacol Exp Ther. 2009 Dec;331(3):827-35. doi: 10.1124/jpet.109.156562. Epub 2009 Sep 9.

21.

Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.

Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS.

J Med Chem. 2009 Sep 10;52(17):5408-19. doi: 10.1021/jm900809r.

PMID:
19725580
22.

Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.

Wan ZK, Chenail E, Xiang J, Li HQ, Ipek M, Bard J, Svenson K, Mansour TS, Xu X, Tian X, Suri V, Hahm S, Xing Y, Johnson CE, Li X, Qadri A, Panza D, Perreault M, Tobin JF, Saiah E.

J Med Chem. 2009 Sep 10;52(17):5449-61. doi: 10.1021/jm900639u.

PMID:
19673466
23.

ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

Zask A, Verheijen JC, Curran K, Kaplan J, Richard DJ, Nowak P, Malwitz DJ, Brooijmans N, Bard J, Svenson K, Lucas J, Toral-Barza L, Zhang WG, Hollander I, Gibbons JJ, Abraham RT, Ayral-Kaloustian S, Mansour TS, Yu K.

J Med Chem. 2009 Aug 27;52(16):5013-6. doi: 10.1021/jm900851f.

PMID:
19645448
24.

2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer.

Chen Z, Venkatesan AM, Dehnhardt CM, Dos Santos O, Delos Santos E, Ayral-Kaloustian S, Chen L, Geng Y, Arndt KT, Lucas J, Chaudhary I, Mansour TS.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):4980-3. doi: 10.1016/j.bmcl.2009.07.070. Epub 2009 Jul 17.

PMID:
19640711
25.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

26.

Heteroaryl ethers by oxidative palladium catalysis of pyridotriazol-1-yloxy pyrimidines with arylboronic acids.

Bardhan S, Wacharasindhu S, Wan ZK, Mansour TS.

Org Lett. 2009 Jun 18;11(12):2511-4. doi: 10.1021/ol900592b.

PMID:
19514789
27.

Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.

Tsou HR, Liu X, Birnberg G, Kaplan J, Otteng M, Tran T, Kutterer K, Tang Z, Suayan R, Zask A, Ravi M, Bretz A, Grillo M, McGinnis JP, Rabindran SK, Ayral-Kaloustian S, Mansour TS.

J Med Chem. 2009 Apr 23;52(8):2289-310. doi: 10.1021/jm801026e.

PMID:
19317452
28.

Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine.

Salaski EJ, Krishnamurthy G, Ding WD, Yu K, Insaf SS, Eid C, Shim J, Levin JI, Tabei K, Toral-Barza L, Zhang WG, McDonald LA, Honores E, Hanna C, Yamashita A, Johnson B, Li Z, Laakso L, Powell D, Mansour TS.

J Med Chem. 2009 Apr 23;52(8):2181-4. doi: 10.1021/jm900075g.

PMID:
19309081
29.

A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).

Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS.

J Med Chem. 2009 Apr 9;52(7):1799-802. doi: 10.1021/jm900093d.

PMID:
19278250
30.

Oxidative palladium catalysis in S(N)Ar reactions leading to heteroaryl ethers from pyridotriazol-1-yloxy heterocycles with aryl boronic acids.

Wacharasindhu S, Bardhan S, Wan ZK, Tabei K, Mansour TS.

J Am Chem Soc. 2009 Apr 1;131(12):4174-5. doi: 10.1021/ja808622z.

PMID:
19265423
31.

Kinase domain mutations in cancer: implications for small molecule drug design strategies.

Bikker JA, Brooijmans N, Wissner A, Mansour TS.

J Med Chem. 2009 Mar 26;52(6):1493-509. doi: 10.1021/jm8010542. No abstract available.

PMID:
19239229
32.

Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2009 Feb;53(2):370-84. doi: 10.1128/AAC.01047-08. Epub 2008 Nov 10.

33.

Targeting Val 216 in class A beta-lactamases with tricyclic 6-methylidene penems.

Venkatesan A, Agarwal A, Abe T, Ushirogochi H, Takasaki T, Mihira A, Mansour TS.

ChemMedChem. 2008 Nov;3(11):1658-61. doi: 10.1002/cmdc.200800167. No abstract available.

PMID:
18924212
34.

Structure-based optimization of protein tyrosine phosphatase-1 B inhibitors: capturing interactions with arginine 24.

Wan ZK, Lee J, Hotchandani R, Moretto A, Binnun E, Wilson DP, Kirincich SJ, Follows BC, Ipek M, Xu W, Joseph-McCarthy D, Zhang YL, Tam M, Erbe DV, Tobin JF, Li W, Tam SY, Mansour TS, Wu J.

ChemMedChem. 2008 Oct;3(10):1525-9. doi: 10.1002/cmdc.200800188. No abstract available.

PMID:
18798205
35.

The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.

Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin SR, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O'Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM.

ChemMedChem. 2008 Oct;3(10):1508-15. doi: 10.1002/cmdc.200800168. No abstract available.

PMID:
18729128
36.

Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.

Xiang J, Wan ZK, Li HQ, Ipek M, Binnun E, Nunez J, Chen L, McKew JC, Mansour TS, Xu X, Suri V, Tam M, Xing Y, Li X, Hahm S, Tobin J, Saiah E.

J Med Chem. 2008 Jul 24;51(14):4068-71. doi: 10.1021/jm8004948. Epub 2008 Jun 26.

PMID:
18578516
37.

Inhibition of OXA-1 beta-lactamase by penems.

Bethel CR, Distler AM, Ruszczycky MW, Carey MP, Carey PR, Hujer AM, Taracila M, Helfand MS, Thomson JM, Kalp M, Anderson VE, Leonard DA, Hujer KM, Abe T, Venkatesan AM, Mansour TS, Bonomo RA.

Antimicrob Agents Chemother. 2008 Sep;52(9):3135-43. doi: 10.1128/AAC.01677-07. Epub 2008 Jun 16.

38.

The development of HKI-272 and related compounds for the treatment of cancer.

Wissner A, Mansour TS.

Arch Pharm (Weinheim). 2008 Aug;341(8):465-77. doi: 10.1002/ardp.200800009. Review.

PMID:
18493974
39.

5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases.

Venkatesan AM, Agarwal A, Abe T, Ushirogochi H, Ado M, Tsuyoshi T, Dos Santos O, Li Z, Francisco G, Lin YI, Petersen PJ, Yang Y, Weiss WJ, Shlaes DM, Mansour TS.

Bioorg Med Chem. 2008 Feb 15;16(4):1890-902. Epub 2007 Nov 5.

PMID:
18061461
40.

The scope and mechanism of phosphonium-mediated S(N)Ar reactions in heterocyclic amides and ureas.

Wan ZK, Wacharasindhu S, Levins CG, Lin M, Tabei K, Mansour TS.

J Org Chem. 2007 Dec 21;72(26):10194-210. Epub 2007 Nov 29.

PMID:
18044930
41.

Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines.

Toral-Barza L, Zhang WG, Huang X, McDonald LA, Salaski EJ, Barbieri LR, Ding WD, Krishnamurthy G, Hu YB, Lucas J, Bernan VS, Cai P, Levin JI, Mansour TS, Gibbons JJ, Abraham RT, Yu K.

Mol Cancer Ther. 2007 Nov;6(11):3028-38. Epub 2007 Nov 7.

42.

On the absolute configuration in 1,4-dihydrothiazepine covalent complexes derived from inhibition of class A and C beta-lactamases with 6-methylidene penems.

Mansour TS, Agarwal A, Venkatesan A, Abe T, Mihira A, Takasaki T, Sato K, Ushirogochi H, Yamamura I, Isoda T, Li Z, Yang Y, Kumagai T.

ChemMedChem. 2007 Dec;2(12):1713-6. No abstract available.

PMID:
17868160
43.

Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.

Wilson DP, Wan ZK, Xu WX, Kirincich SJ, Follows BC, Joseph-McCarthy D, Foreman K, Moretto A, Wu J, Zhu M, Binnun E, Zhang YL, Tam M, Erbe DV, Tobin J, Xu X, Leung L, Shilling A, Tam SY, Mansour TS, Lee J.

J Med Chem. 2007 Sep 20;50(19):4681-98. Epub 2007 Aug 17.

PMID:
17705360
44.

Dimethyl sulfoxide mediated elimination reactions in 3-aryl 2,3-dihalopropanoates: scope and mechanistic insights.

Li W, Li J, Lin M, Wacharasindhu S, Tabei K, Mansour TS.

J Org Chem. 2007 Aug 3;72(16):6016-21. Epub 2007 Jul 12.

PMID:
17628103
45.

Naphthyl tetronic acids as multi-target inhibitors of bacterial peptidoglycan biosynthesis.

Mansour TS, Caufield CE, Rasmussen B, Chopra R, Krishnamurthy G, Morris KM, Svenson K, Bard J, Smeltzer C, Naughton S, Antane S, Yang Y, Severin A, Quagliato D, Petersen PJ, Singh G.

ChemMedChem. 2007 Oct;2(10):1414-7. No abstract available.

PMID:
17600795
46.

beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action.

Xiang J, Ipek M, Suri V, Tam M, Xing Y, Huang N, Zhang Y, Tobin J, Mansour TS, McKew J.

Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. Epub 2007 Apr 25.

PMID:
17490884
47.

Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase.

Nittoli T, Curran K, Insaf S, DiGrandi M, Orlowski M, Chopra R, Agarwal A, Howe AY, Prashad A, Floyd MB, Johnson B, Sutherland A, Wheless K, Feld B, O'Connell J, Mansour TS, Bloom J.

J Med Chem. 2007 May 3;50(9):2108-16. Epub 2007 Apr 3. Erratum in: J Med Chem. 2007 Nov 29;50(24):6290.

PMID:
17402724
48.

Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.

Venkatesan AM, Agarwal A, Abe T, Ushirogochi H, Yamamura I, Ado M, Tsuyoshi T, Dos Santos O, Gu Y, Sum FW, Li Z, Francisco G, Lin YI, Petersen PJ, Yang Y, Kumagai T, Weiss WJ, Shlaes DM, Knox JR, Mansour TS.

J Med Chem. 2006 Jul 27;49(15):4623-37.

PMID:
16854068
49.
50.

Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.

Gopalsamy A, Chopra R, Lim K, Ciszewski G, Shi M, Curran KJ, Sukits SF, Svenson K, Bard J, Ellingboe JW, Agarwal A, Krishnamurthy G, Howe AY, Orlowski M, Feld B, O'Connell J, Mansour TS.

J Med Chem. 2006 Jun 1;49(11):3052-5.

PMID:
16722622

Supplemental Content

Loading ...
Support Center